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Abstract
Aims The detection of non-ischaemic (mainly hypertension, diabetes, and obesity) stage B heart failure (SBHF) may facilitate
the recognition of those at risk of progression to overt HF and HF prevention. We sought the relationship of speciﬁc
electrocardiographic (ECG) markers of SBHF to echocardiographic features of SBHF and their prognostic value for development
of HF. The ECG markers were Cornell product (Cornell-P), P-wave terminal force in lead V1 (PTFV1), ST depression in lead V5
V6 (minSTmV5V6), and increased heart rate. Echocardiographic assessment of SBHF included left ventricular hypertrophy
(LVH), impaired global longitudinal strain (GLS), and diastolic dysfunction (DD).
Method and results Asymptomatic subjects ≥65 years without prior cardiac history, but with HF risks, were recruited from
the local community. At baseline, they underwent clinical assessment, 12-lead ECG, and comprehensive echocardiography.
New HF was assessed clinically at mean follow-up of 14 ± 4 months, and echocardiography was repeated in subjects with
HF. Of the 447 study subjects (age 71 ± 5, 47% men) with SBHF, 13% had LVH, 32% impaired GLS, and 65% ≥grade I DD
(10% ≥grade II DD). Forty were lost to follow-up. Clinical HF developed in 47 of 407, of whom 20% had echocardiographic
LVH, 51% abnormal GLS, and 76% DD at baseline. Baseline LVH and abnormal GLS (not grade I DD) were independently
associated with outcomes (clinical HF and cardiovascular death). Cornell-P and heart rate (not minSTmV5V6 nor PTFV1) were
independently associated with LVH, impaired GLS, and DD. Cornell-P and minSTV5V6 (not heart rate nor PTFV1) were
independently associated with outcomes. More ECG abnormalities improved sensitivity, but ECG-markers were not
independent of or incremental to echocardiographic markers to predict HF in SBHF.
Conclusions In this elderly study population, ECG markers showed low diagnostic sensitivity for non-ischaemic SBHF and low
prognostic value for outcomes. Cornell-P and minSTmV5V6 had predictive value for outcomes in non-ischaemic SBHF
independent of age, gender, and common comorbidities but were not incremental to echocardiography.
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Introduction
Stage B heart failure (SBHF) is an early stage of heart failure
(HF) with no symptoms despite evidence of cardiac structural
or functional impairment.1,2 Most often it is due to loss of
functioning myocytes from myocardial infarction, valvular
disease, or left ventricular hypertrophy (LVH) secondary to
hypertension.1 Randomized trials have shown that early
intervention can prevent or delay the onset of overt HF in
patients with reduced left ventricular ejection fraction (LVEF)
in the ischaemic population.3,4 However, evidence is missing
in the non-ischaemic population with preserved LVEF about
utility of early diagnosis and treatment. Using
echocardiography, SBHF may be detected by LVH, diastolic
dysfunction (DD), or impaired global longitudinal systolic
strain (GLS).2 The assessment of left ventricular (LV) function
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has been strengthened by speckle-tracking echocardiography.
This semi-automated method is highly sensitive for the
detection of subtle myocardial impairment, provides
incremental prognostic value over LVEF5 and can be
considered to be a functional marker of SBHF.2,6 However,
the cost and feasibility of current echocardiographic
techniques are a barrier to community-based screening for
SBHF. A selective screening strategy of identifying high-risk
individuals based on the use of simpler tools that are more
feasible could improve the efﬁciency of a screening approach.
The association of abnormal electrocardiographic (ECG)
markers and incident HF has been reported in the literature,
including abnormal QRS duration,7 abnormal P-wave terminal
force in lead V1(PTFV1),8 ST changes,9 and various markers in
combination.10,11 ECG-LVH has been associated with
abnormal cardiac function and has predictive value for
incident HF independent of echocardiographic LVH.12 ECG-
LVH by Cornell product (Cornell-P) criteria is strongly
associated with DD,13 and in a larger cohort of hypertensive
patients, ECG-LVH was associated with increased risk of LV
systolic dysfunction,14 especially when combined with ST
depression in the lateral precordial leads (V5–V6), even in
the absence of coronary disease.15,16 ECG markers [Cornell-
P, PTFV1, minimal ST deviation at m point of leads V5 and
V6 (minSTmV5V6), and abnormally increased heart rate]
may reﬂect underlying structural changes in the heart. Their
associations with outcome have not been well studied.
Accordingly, we aimed to evaluate the performance of
commonly utilized ECG markers to predict echocardiographic
features of SBHF2 and to compare the prognostic and
incremental value of these ECG markers with
echocardiographic indices for HF in this community
population at risk of HF.
Materials and methods
Study population
Participants were enrolled through local media advertising.
Data were prospectively collected from subjects ≥65 years
old and living in the community. Inclusion was based on the
presence of one or more of HF risk factors: (i) hypertension
(based on systolic blood pressure (SBP) >140 mmHg and/or
self-report of anti-hypertensive medication); (ii) type 2
diabetes mellitus (T2DM; based on self-report of diagnosis
including medication); (iii) obesity [body mass index (BMI)
≥30 kg/m2]; (iv) previous potentially cardio toxic
chemotherapy; (v) family history of HF; and (vi) previous
history of heart disease (but not existing HF). Excluded were
subjects with (i) symptoms or a known history of HF; (ii)
known coronary artery disease (CAD) including history of
myocardial infarction and coronary artery bypass graft; (iii)
more than moderate valvular heart disease; (iv) reduced LVEF
(<40%) on baseline echocardiography; (v) atrial ﬁbrillation;
and (vi) inability to acquire interpretable images at baseline.
This study was performed in accordance with a research
protocol approved by the Tasmanian Human Research Ethics
Committee and registered with the Australian and New
Zealand Clinical Trials Registry (http://www.anzctr.org.au/;
ACTRN12614000080628). Individual written informed
consent was obtained from all participants
Data collection
Data were prospectively collected at facilities in the
community from all participants enrolled in the study. All
underwent a physical examination and symptom
questionnaire. Anthropometric measurements were
obtained, and BMI was calculated [body weight (kg)/height2
(m2)]. Blood pressure was measured twice after 10 min of
rest. Data were also collected on socio-economic indicators,
complete medical history, and family history. Charlson
comorbidity score index was used for comorbidity
assessment.17
Electrocardiogram
A standard 12-lead ECG was recorded at 25 mm/s and
1 mV/cm according to standard protocol. ECG measurements
were performed using MUSE software (GE Healthcare,
Milwaukee, WI, USA) including QRS duration and axis, PR,
QT, and heart rate. Cornell voltage (Cornell-V) was measured
as SV3 + RaVL, and criteria for LVH were deﬁned as ≥2.8 mV
(28 mm) in men and ≥2.0 mV (20 mm) in women.14 Criteria
for LVH using the Cornell-P (the product of QRS duration
times Cornell-V [RaVL + SV3] plus 6 mm in women) was deﬁned
as ≥2440 mm · ms,14 and the 75th percentile of gender
speciﬁc cut-offs for Cornell-P from the current study
population were also used as categorical cut-off. Sokolow-
Lyon voltage (SLV) was measured as SV1 + RV5 or RV6, and
criteria for LVH were deﬁned as ≥3.5 mV (35 mm).18 The
cut-off for absolute ST segment deviation (minSTmV5V6,
the midpoint of the ST segment on median complexes in
leads V5 and V6) was deﬁned using upper 75th percentile
of the cohort as 20 μV. Abnormal P-wave terminal force
in the right precordial lead V1 [PTFV1; the product of the
negative P-wave deﬂection from onset of the negative
deﬂection to its nadir in lead V1 (μV) and the duration
(ms)] was deﬁned as ≤4000 μVms.8 An abnormal ECG was
deﬁned as the combination of >1 of the following: (i) resting
heart rate ≥80 beat per minute (upper 90th percentile); (ii)
upper 75th percentile of Cornell-P; (iii) upper 75th percentile
of minSTmV5V6; and (iv) abnormal PTFV1.
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Echocardiographic study
Standard transthoracic 2D and Doppler echocardiographic
studies were performed using standard equipment (Siemens
ACUSON SC2000, Siemens Healthcare, Mountain View, CA,
USA) and transducer (4V1c, 1.25–4.5 MHz; 4Z1c, 1.5–
3.5 MHz) in accordance with the American Society of
Echocardiography guidelines.19 LV dimensions during diastole
and systole and wall thicknesses were measured according to
the recommended criteria, and LV mass index (LVMi) was
calculated accordingly.19 Echocardiographic LVH (Echo-LVH)
was deﬁned as LVMi >115 g/m2 in men and >95 g/m2 in
women. LV and left atrial volumes were calculated by the
Simpson biplane method19 indexed to body surface area. Left
atrial enlargement deﬁned as left atrium volume index
≥34 mL/m2. Mitral inﬂow peak early diastolic velocity (E),
peak late diastolic velocity (A), E/A ratio, and E wave
deceleration time were measured for diastolic function
assessment.20,21 Tissue Doppler mitral annular early diastolic
velocity (e’) was assessed at septal and lateral and averaged
for calculation of E/e’; septal E/e’ ≥15, lateral E/e’ ≥13, and
averaged ≥13 were deﬁned as abnormal.21 DD grade was
deﬁned as previously described as21,22 grade I DD: E/A
<0.8, E/e’ <10, pulmonary venous inﬂow S > D; grade II
DD: 0.8 < E/A <1.5, E/e’ >13 or left atrial enlargement, or
presence of mid-diastolic forward ﬂow (L wave), or positive
Valsalva (>50% decrease of E/A ratio); grade III DD: E/A
>1.5, deceleration time <140 ms.
Left ventricular longitudinal strain measurements were
obtained from grey scale-recorded images in the apical
four-chamber, two-chamber, and long-axis views. Strain was
analysed using velocity vector imaging (Syngo VVI, Siemens
Medical Solutions). GLS was measured online by averaging
all 18 segment strain from apical four-chamber, two-chamber,
and long-axis views. Impaired GLS was deﬁned using cut-off
of <18%.23 Global circumferential strain was measured
ofﬂine. Global diastolic strain was obtained by averaging all
18 segment strain values and measured according to method
published by Ishii et al.24 Functional capacity was assessed
using a 6-min walk test distance following a standardized
protocol.25
Follow-up and primary endpoint
Potential HF symptoms were assessed through regular
follow-up phone calls, followed by symptom surveillance
questionnaires and clinical visits. Possible HF signs and
symptoms were reviewed by three independent
cardiologists, and the HF diagnosis was conﬁrmed using the
Framingham criteria with the presence of two major or one
major and two minor criteria.26 The primary composite
endpoint was deﬁned as new onset of HF or death from
cardiovascular (CV) causes. Follow-up echocardiographic
assessment of LVEF was performed to classify the patients
with HF with reduced (HFrEF, LVEF <40%), mid-range
(HFmrEF, LVEF 40–49%) or preserved EF.27
Statistical analysis
Data are presented as mean [±standard deviation (SD)] after
testing for normal distribution (Shapiro–Wilk test). Data
deviating from normality are expressed as median
(interquartile range). Categorical variables are expressed as
percentages. Correlation between variables was assessed
with Pearson or Spearman correlation coefﬁcients. For
differences among groups, Mann–Whitney U test or t-test
were used for continuous variables. Pearson’s χ2 tests or
Fisher’s exact test were used for categorical variables.
Logistic regression analysis was used to examine the
association of ECG markers and abnormal echocardiographic
features of SBHF. The primary outcome of time to event
was examined with univariable and multivariable
Cox proportional hazards models. Receiver operator
characteristic analysis was used to examine the
discriminative ability of variables for outcome. Comparisons
of areas under the curve were performed with the method
suggested by Hanley and McNeil. Survival analysis was
performed using the Kaplan–Meier method, and the
differences in survival between groups were assessed by
the log-rank test. Net reclassiﬁcation improvement (NRI)
was based on quartile boundaries of probability calculated
from the multivariable logistic regression for incremental
value of ECG markers over clinical and echocardiographic
measures for outcome. Statistical analyses were performed
using a standard statistical software package (SPSS software
22.0, SPSS Inc., Chicago, IL). Statistical signiﬁcance was
deﬁned by P < 0.05.
Results
Patient selection
Baseline ECG and echocardiography were obtained in 447
individuals from the community (age 71 ± 5 years, 47%
men) who met the inclusion criteria. HF risk factors were
present in all—most commonly hypertension (81%), T2DM
(54%), and obesity (45%); 81% had more than one of the
listed risk factors. The echocardiographic markers of SBHF
were LVH (13%), DD (65% by ≥grade 1 DD and 10% by
≥grade 2 DD), and impaired GLS (32%). The median
(interquartile range) for Cornell-V was 9.8 (6.8–13.6) mm;
SLV 18.0 (14.1–22.7) mm, Cornell-P 1090 (786–
1500) mm · ms. The mean (±SD) of minSTV5V6 was
3.1 ± 39 (μV) and PTFV1 2918 ± 3532 (μVms). Using the
conventional cut-off values, ECG-LVH was present in 1.6%
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by SLV, 2% by Cornell-V, and 3.1% by Cornell-P. Abnormal
PTFV1 was present in 35%, abnormal minSTmV5V6 in 27%,
and increased heart rate in 13%.
Association of electrocardiographic markers with
echocardiographic feature of stage B heart failure
Baseline demographic, ECG, and echocardiographic
characteristics are listed in Table 1, stratiﬁed according to
the presence SBHF features. Subjects with LVH and DD were
older, but impaired GLS was unrelated to age. However, more
men had impaired GLS than women. Mean BMI was not
different among groups. Hypertension and obesity were
more prevalent in subjects with LVH; T2DM and obesity were
more prevalent in subjects with impaired GLS. Functional
capacity by 6-min walk test was lower in those with DD
(P = 0.02).
Using continuous measures, Cornell-V and Cornell-P were
signiﬁcantly higher in groups with Echo-LVH, DD, and
impaired GLS (P ≤ 0.023). SLV showed no differences among
the groups. The overall prevalence of ECG evidence of LVH
(ECG-LVH) by the conventional criteria was the greatest by
Cornell-P—detected in 8.6% of Echo-LVH, 4.5% of DD, and
6.3% of impaired GLS. By SL voltage and Cornell-V, only
5.2% and 3.4% in Echo-LVH were abnormal, respectively.
The 75th percentile gender speciﬁc cut-off of Cornell-P for
LVH from the current cohort was 1442 mm · ms for men
and 1518 mm · ms in women; this cut-off detected 45% of
those with Echo-LVH but also detected 22% of those with
no Echo-LVH as being abnormal. The 75th percentile cut-off
for minSTmV5V6 was 20 μV. This cut-off showed no
differences among the groups. As ECG markers are gender
dependent, we further assessed their correlation with each
SBHF feature stratiﬁed by gender (Table A1). In general,
correlation between men was better than women. There
was signiﬁcant correlation of Cornell-V and Cornell-P with
LVMi, with better correlation using Cornell product than
voltage. Correlation with GLS and e’ were similarly better
with Cornell-P. SLV showed insigniﬁcant correlation.
MinSTmV5V6 showed signiﬁcant correlation with LVMi and
GLS. The overall discriminative ability of four ECG markers
for SBHF features is displayed by receiver operating
characteristic curve in Figure 1.
The independent associations of ECG markers with SBHF
features are summarized in Table 2. Cornell-P and resting
heart rate were associated with Echo-LVH, DD, and impaired
GLS independent of age, gender, SBP, BMI, Charlson
comorbidity score, and other ECG markers. One SD of the
mean increased Cornell-P (635 mm · ms) was associated with
an odds ratio that was 1.48 for Echo-LVH, 1.38 for DD, and
1.37 for impaired GLS (P < 0.012) independent of clinical
variables. In multivariable analysis with all four ECG markers,
the independent association of Cornell-P and increased
resting heart rate remained signiﬁcant, with similar effect size
(P < 0.047) (Table 2).
Predeﬁned cut-offs of the four abnormal ECG markers
were assessed for diagnostic characteristics for echo features
of SBHF. The diagnostic characteristics including sensitivity
and positive predictive value for detection of
echocardiographic LVH, DD, and impaired GLS are
summarized in Table 3. Sensitivity was overall low using
single marker, which improved slightly using combined
markers with the expected loss of speciﬁcity from including
multiple variables.
Association of electrocardiographic markers with
primary outcome
After a median interval of 14 ± 4 months, 40 individuals were
lost to follow-up or alive but unable to attend follow-up. This
group was no different from the remaining 407 individuals
who completed follow-up (Table A2). New HF symptoms
developed in 47 patients and 4 died (2 of CV causes). Of
the 47 who developed symptoms, none was preceded by an
acute coronary event. The primary composite endpoint of
new onset of HF and CV death occurred in 49 (12%) of the
entire cohort—an annualized event rate of 10%. Medication
status (angiotensin-converting-enzyme inhibitor/angiotensin
receptor blocker, beta-blocker, and calcium antagonists) was
not associated with outcome (P > 0.09). The diagnosis of
HF was a clinical one, but the nature of HF was identiﬁed
by echocardiography—only 1 of 47 patients with new-onset
HF had HFrEF, 4 had HFmrEF, and 42 had preserved EF.
In the Kaplan–Meier analysis of the four abnormal ECG
markers, log-rank testing showed only individuals with
abnormal Cornell-P (upper 75th percentile), which was
associated with primary outcome (P = 0.04) and not those
with minSTmV5V6 (P = 0.15) nor with abnormal PTFV1
(P = 0.26) and abnormal heart rate (P = 0.59). Of the entire
cohort, 66% had at least one abnormal ECG marker, 29%
had two, and 7% had ≥3. Figure 2 shows adverse outcome
that was proportional to the number of abnormal ECG
markers.
The independent and incremental predictive value of
common ECG and echocardiographic markers for primary
outcome was examined using continuous (per SD) in
univariable as well as series of multivariable Cox regression
models. In univariable analysis, Cornell-V (not SLV), Cornell-
P, minSTmV5V6 (not PTFV1), and LVMi and GLS (not DD)
were signiﬁcant predictors for outcome (P < 0.026). The
75th percentile of Cornell-P showed predictive value, and this
association remained signiﬁcant after adjusting for age,
gender, and Charlson comorbidity score (Table 4).
The four ECG markers (Cornell-P, minSTmV5V6, PTFV1, and
abnormal heart rate ≥80 bpm) were moderately correlated
(correlation coefﬁcient: 0.01 to 0.42). When they were
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entered into the models together with age, gender, and
Charlson comorbidity score, Cornell-P and minSTmV5V6
remained to be signiﬁcantly association with outcome. In
the subsequent analyses with echocardiographic markers
entered into models, the association of either Cornell-P
or minSTmV5V6 became insigniﬁcant with the presence
of either LVMi or GLS, indicating a much stronger
association of echocardiographic features with outcome
(Table 4).
The incremental value of ECG markers over clinical
measures (with and without echocardiographic features)
was examined using NRI analysis. Addition of abnormal ECG
to clinical information (model I), clinical + any one echo
marker (model II), and any two echo markers did not
demonstrate any signiﬁcant incremental value for outcome
with better performance of adding two ECG markers than
one (NRI = 0.01 to 0.11, P > 0.065) (Table A3).
Figure 3 demonstrates the association of abnormal ECG
(ECG+) with outcome in the presence of one (Figure 3A) or
more than one (Figure 3B) abnormal echo markers. Results
showed that in patients with mild cardiac abnormalities
(one abnormal echo), the presence of abnormal ECG is
signiﬁcantly associated with outcome (hazard ratio: 2.2,
1.04–4.68, P = 0.04) regardless of echo status.
Abnormal ECG appeared to have prognostic value in
those with mild disturbances of cardiac structure and
function by echocardiography, although generally more
prognostic information appeared to be obtainable from
echocardiography. Abnormal ECG did not add incremental
value to clinical and echocardiographic assessment (Figure 4).
Figure 1 Receiver operating characteristic curve of common ECG markers for descriminative characteristics for echocardiographic LVH, impaired global
longitidunal strain (GLS), and for abnormal E/e’ (cut-off 13).
Table 2. Multivariable logistic regression for association and prediction of echocardiographic features of stage B heart failure
Left ventricular
hypertrophy
Diastolic
dysfunction
Impaired
GLS (<18%)
R2 OR (95% CI) P value R2 OR (95% CI) P value R2 OR (95% CI) P value
Models with each of following:a
Heart rate (11 bpm) 0.083 0.73 (0.54, 0.99) 0.044 0.181 1.41 (1.13, 1.76) 0.003 0.136 1.54 (1.24, 1.91) <0.001
Cornell product
(635 mm · ms)
0.101 1.48 (1.14, 1.90) 0.003 0.175 1.38 (1.08, 1.78) 0.012 0.116 1.37 (1.11, 1.69) 0.003
minSTmV5V6 (39 μV) 0.080 0.75 (0.55, 1.01) 0.058 0.157 0.92 (0.74, 1.13) 0.420 0.098 0.84 (0.68, 1.04) 0.843
PTFV1 (3532 μVms) 0.075 1.24 (0.94, 1.64) 0.136 0.156 0.93 (0.75, 1.15) 0.521 0.091 0.98 (0.79, 1.21) 0.866
Model with all the following:
Heart rate (11 bpm) 0.134 0.72 (0.53, 0.99) 0.047 0.199 1.39 (1.10, 1.75) 0.005 0.158 1.52 (1.22, 1.90) <0.001
Cornell product
(635 mm · ms)
1.49 (1.13, 1.96) 0.004 1.39 (1.05, 1.84) 0.021 1.31 (1.04, 1.65) 0.021
minSTmV5V6 (39 μV) 0.87 (0.63, 1.19) 0.379 1.02 (0.81, 1.29) 0.872) 0.92 (0.73, 1.16) 0.492
PTFV1 (3532 μVms) 1.27 (0.92, 1.67) 0.166 0.98 (0.78, 1.23) 0.853 1.06 (0.85, 1.33) 0.606
CI, conﬁdence interval; GLS, global longitudinal strain; minSTmV5V6, minimal ST deviation at m point of leads V5 and V6; OR, odds ratio;
PTFV1, P-wave terminal force measured at lead V1.
Each model contains age, gender, heart rate, SBP, BMI, Charlson comorbidity score; LIFE: using cut-offs from LIFE study as stated in
methods.
aValue as per standard deviation.
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Discussion
In this heterogeneous, community cohort with known
non-ischaemic HF risks and preserved EF, we did not ﬁnd
ECG markers to be of value in screening for SBHF because
of low prevalence, low sensitivity, and low predictive value,
compared with echocardiographic features of SBHF.
However, a number of associations between ECG and new
indices of LV dysfunction and outcome were identiﬁed.
Cornell-P and increased resting heart rate were
independently associated with echocardiographic SBHF
features. Cornell-P and minSTmV5V6 were associated with
primary outcome independent of clinical measures but not
independent of or incremental to echocardiographic
measures.
Stage B heart failure is deﬁned as a condition with
asymptomatic structural and/or functional changes in the
heart. The clinical recognition of early HF can be difﬁcult,
and the prevalence of incident HF may vary broadly
depending on the diagnostic criteria.28,29 A recent meta-
analysis reported that incident HF diagnosis in 8 out of 15
included studies was based on a non-standardized clinical
description.30 Differences in the diagnostic criteria for HF
may have impact on the outcome assessment in these
studies. Among four commonly used HF diagnostic criteria
(Framingham, Boston, Gothenburg, and European Society of
Cardiology criteria),31 there were signiﬁcant differences in
predicting clinically relevant outcomes including incidentTa
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Figure 3 The presence of echo features of stage B heart failure with/without abnormal electrocardiogram (ECG) and associated outcome. Abnormal
ECG was deﬁned as presence of any two abnormal ECG marker (Cornell-P, minSTmV5V6, PTFV1, and baseline HR). Abnormal echo was deﬁned as the
presence of any one (A) or >1 (B) of LVH, impaired GLS (18% cut-off), and diastolic dysfunction. Abnormal ECG and normal echo (ECG+/Echo, coded
red) is associated with worst outcome in mild SBHF by presence of 1 echo marker (A). More cardiac impairment (deﬁned by >1 echo marker) is
associated with worse outcome regardless of their ECG status (B).
Figure 4 Incremental prognostic value of abnormal electrocardiogram (ECG) over clinical and abnormal echocardiographic markers of stage B heart
failure. Clinical includes age, gender, and Charlson comorbidity score; abnormal ECG was deﬁned as the presence of any one of (75th percentile of
Cornell product; minSTmV5V6, PTFV1, and heart rate); Abnormal echo was deﬁned as the presence of any one, two, or all three of LVH, impaired
GLS (18% cut-off), and diastolic dysfunction. This ﬁgure shows that the presence of more abnormal ECG markers had relative incremental prognostic
value over clinical information only and when only one abnormal echo marker was present.
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hospital admission. The Framingham criteria seems to
correlate best with echocardiography, which is the gold
standard to diagnose HF.31
Accordingly, we used the Framingham HF criteria to
select subjects with HF. Echocardiography was performed
in the subjects with HF to evaluate LVEF. Although we
excluded any known and possible HF at baseline, the
annualized rate of incident HF was 10%. A higher
proportion of stage C1 at baseline may partially explain
this.32 Individuals in stage C1 have a signiﬁcantly worse
outcome than SBHF. A high incidence rate was observed
in another community study of a cohort with combined
diabetes and hypertension,33 in whom E/e’ >15 (detected
in 23%) was used to categorize SBHF. In our cohort, the
prevalence of increased E/e’ was lower in entire cohort
(12%) but was similar in those with both hypertension
and T2DM (20%).
In this study, we provided a comprehensive assessment of
early markers of myocardial dysfunction (DD and strain
imaging) in addition to assessment of structural cardiac
changes. In the non-ischaemic population with preserved
LVEF, impaired GLS and DD, and LVH have a comparable
effect on functional capacity.2 The current guidelines have
recommended that strain could be used in asymptomatic
subjects at risk of HF for early detection of preclinical
myocardial dysfunction.27 Indeed, this is feasible in the
community—a number of community-based studies have
used strain, including the Northern Manhattan study,34
Framingham study,35 the CARDIA study,36 and others.
Previous studies in a different population, with a signiﬁcant
proportion of ischaemic disease have demonstrated the
association of ECG changes of LVH with DD.13 The association
of ECG features of LVH with systolic function is based on LV
midwall shortening, which is likely to be affected by LV
geometry.14 Using speckle-tracking echocardiography, a
sensitive imaging marker for early myocardial damage, which
has been linked to outcomes.5 This study conﬁrmed the
association of ECG markers with early systolic changes by
impaired GLS, and these associations were independent of
clinical measures including blood pressure, BMI, and
comorbidities such as diabetes and hypertension. The
potential mechanisms linking abnormal ECG markers and
depressed systolic function are multiple. Ischaemia could be
an important contributor and is hard to exclude in a cohort
with a high prevalence of hypertension and diabetes.14
Myocardial interstitial ﬁbrosis is another possible and
important link.
Screening for SBHF in the non-ischaemic population is
challenging, because of a lack of feasible and effective
markers. LVH is widely used as an important feature of
SBHF and can be diagnosed by ECG or echocardiography.
The association of ECG-LVH with risk of incident HF has
been widely recognized in a recent meta-analysis.30
ECG-LVH and echocardiographic LVH were found to be
equally predictive of incident HF in a community study
after follow-up of 12 years.12 Thus, ECG-LVH has been
used as established risk component in two widely used
HF risk scores.37,38 Other studies have proposed an
independent and incremental prognostic signiﬁcance of
ECG-LVH over echocardiography.39,40 However, the
prevalence of ECG-LVH is known to be low, varies from
0.6–40%, with an average of 18% only if using combined
multiple diagnostic criteria.41 In the process of screening,
a single ECG marker may be insufﬁciently effective
because of its low sensitivity and low positive predictive
value.42 In a community-based study, Gencer et al. studied
predictive value of combined multiple ECG makers. He
found combined abnormal ECG markers were present in
up to 34% of population and were signiﬁcantly
incremental to clinical measures.10 Given its safety, low
cost, and wide availability and a ﬁrst-line routine
examination, the ECG has an important role in the primary
care. Computerized measurement facilitated a
comprehensive and multi-marker approach for the purpose
of screening. In our study, a combination of four
commonly used ECG measures had only slightly improved
screening sensitivity over one marker. Besides, its
prognostic value showed beneﬁt only in those with early
cardiac changes, compared with echocardiography. Thus,
the value of ECG as a diagnostic and prognostic marker
in SBHF is still controversial.
An effective screening programme needs more than a
feasible screening test. Screening at the primary care level
faces major challenges relating to the feasibility. First, the
approach to screening for SBHF is inﬂuenced by the scope
of target for prevention. The intervention strategy for non-
ischaemic SBHF has not been well deﬁned. It is unknown
whether the presence of increased risk would justify
intervention without evidence of HF. Second, traditional
SBHF based on structural remodelling (LVEF and LVH) needs
to be supplemented by more functional parameters,2 which
are more sensitive and can detect myocardial impairment
prior to the onset of structural remodelling. Although clinical
risk-based and ECG could serve to select higher risk
individuals, echocardiography is still needed for guiding
intervention. Third, the use of biochemical marker and
hand-held ultrasound (HHU) devices. The sensitivity of BNP
may be a particular issue in screening of non-ischaemic HF,
due to the effects of obesity on BNP levels.43 Plasma
natriuretic peptides have been better markers for systolic
HF than they are for HF with preserved EF or preclinical HF
as they reﬂect cardiac wall stress, which can be expected to
be normal until there is an increment of ﬁlling pressure. In
asymptomatic individuals, ﬁndings from studies have been
heterogeneous. The sensitivity and positive predictive values
of natriuretic peptides have been low—for example, the
sensitivity was reported to be 30% against LVH by cardiac
magnetic resonance imaging.44 Despite this inverse
426 H. Yang et al.
ESC Heart Failure 2017; 4: 417–431
DOI: 10.1002/ehf2.12151
relationship, NT-proBNP was reported to provide signiﬁcant
prognostic information in a population study with 21 years
of follow-up.45 Given the limited availability and relative
cost of standard echocardiography, an HHU system may
able to provide a potential substitute. HHU can play an
important role in structural cardiac evaluation. Although
there has been growing interest in its role as a screening
tool in the community, the main limitations relate to its
imaging capabilities—other than assessing LVEF, the
current HHU system does not provide assessment of DD
or GLS.
The present study was a community-based clinical trial.
There are several limitations. First, because the follow-up
period was short, the outcome assessment may be limited.
Second, relatively high rate of incident HF in this cohort
may suggest the presence of unrecognized HF at baseline.
As previously reported, the possibility of high prevalence
of stage C1 in this cohort may explain their rapid progress
to new HF.32 Third, the lack of protection of clinical
outcome by treatment may indicate confounding by
indication that is the most at risk patients were treated in
primary care but were more likely to have events. Fourth,
we did not perform a new echocardiography in all of the
study participants at follow-up, only in subjects with clinical
HF nor did we obtain biomarkers (e.g. BNP), as previous
work showed these were more effective in symptomatic
rather than asymptomatic dysfunction.46 Moreover, the test
performance of BNP is may be constrained in this setting by
increasing patient age, obesity, and insulin resistance,43,46
although recently published data showed controversial
results.45 Fifth, the concomitant presence of CAD was not
investigated. Atherosclerosis may co-exist with diabetic
cardiomyopathy and hypertensive heart disease and may
cause LV dysfunction because of CAD. We sought to exclude
patients with a history consistent with CAD, but we cannot
exclude an ischaemic contribution to the reported cardiac
functional changes. Recruitment was partly through
newspaper advertising, which may have led to a population
selection bias.
Conclusions
Although standard ECG markers showed low sensitivity and
low positive predictive value for SBHF, Cornell-P and
abnormally increased heart rate were independently
associated with LVH, impaired GLS, and DD. Cornell-P and
ST changes showed prognostic value for clinical HF, and death
of CV causes independent of clinical measures but were not
incremental to echocardiography. However, ECG
abnormalities were associated with poor outcome (clinical
HF and death of CV causes) in those with early and mild
echocardiographic features of impairment.
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Appendix
Table A1. Correlation between electrocardiographic markers and cardiac structural and functional measures in men and women
LVMi GLS e’ E/e’ Diastolic strain Diastolic strain rate
Rho P value Rho P value Rho P value Rho P value Rho P value Rho P value
Male
Cornell voltage 0.39 <0.01 0.22 0.002 0.17 0.01 0.05 0.47 0.20 0.004 0.30 <0.01
SL voltage 0.05 0.50 0.09 0.16 0.002 0.97 0.03 0.69 0.10 0.16 0.02 0.73
Cornell product 0.40 <0.01 0.19 0.01 0.19 0.01 0.05 0.50 0.20 0.01 0.27 <0.01
minSTmV5V6 0.30 <0.01 0.15 0.03 0.11 0.10 0.06 0.43 0.07 0.35 0.13 0.07
PTFV1 0.10 0.16 0.06 0.39 0.08 0.23 0.01 0.87 0.05 0.44 0.10 0.17
Female
Cornell voltage 0.18 0.004 0.13 0.04 0.25 <0.01 0.05 0.47 0.14 0.03 0.13 0.04
SL voltage 0.02 0.78 0.02 0.79 0.042 0.52 0.01 0.85 0.12 0.07 0.12 0.07
Cornell product 0.26 <0.01 0.16 0.01 0.21 0.001 0.08 0.22 0.11 0.09 0.13 0.05
minSTmV5V6 0.18 0.01 0.12 0.06 0.07 0.30 0.10 0.13 0.13 0.05 0.17 0.01
PTFV1 0.03 0.69 0.09 0.13 0.13 0.04 0.02 0.73 0.21 0.001 0.12 0.07
GLS, global longitudinal strain; LVMi, left ventricular mass index; minSTmV5V6, minimal ST deviation at m point of leads V5 and V6;
PTFV1, P-wave terminal force measured at lead V1; SL, Sokolow-Lyon.
Table A2. Baseline characteristics in those completed vs. those unable to complete follow-up
Completed follow-up Unable to follow-up
(n = 407) (n = 40) P value
Age (year) 71 ± 5 71 ± 5 0.627
Gender male 196 (48) 12 (30) 0.028
Body mass index (g/m2) 30 ± 5 31 ± 6 0.234
Type 2 diabetes mellitus 218 (54) 23 (58) 0.634
Obese (BMI ≥30 g/m2) 182 (45) 21 (53) 0.346
Hypertension 333 (82) 29 (73) 0.152
Previous chemotherapy 36 (9) 5 (12) 0.445
Family history 147 (36) 13 (33) 0.649
Previous heart condition 29 (7) 6 (15) 0.077
Charlson comorbidity score 1 (0–2) 1 (0–2) 0.595
LV ejection fraction 64 ± 6 64 ± 7 0.770
GLS 18.6 ± 2.5 18.0 ± 2.9 0.404
Mitral E/A 0.8 ± 0.2 0.8 ± 0.2 0.752
Mitral e’ (cm/s) (averaged) 0.08 ± 0.02 0.08 ± 0.02 0.399
E/e’ (averaged) 8.9 ± 2.6 9.0 ± 2.5 0.768
Left atrium volume (mL/m2) 30 ± 9 30 ± 9 0.431
LV mass (g/m2) 84 ± 18 82 ± 16 0.521
Diastolic dysfunction 265 (65) 24 (60) 0.519
Abnormal E/e’13 49 (12) 5 (13) 0.932
LV hypertrophy (echo) 53 (13) 5 (13) 0.925
LA enlargement34 124 (31) 9 (23) 0.289
Abnormal GLS, cut-off 18 129 (32) 13 (33) 0.917
Cornell voltage (mm) 9.9 (7.0–13.7) 8.2 (4.6–12.9) 0.115
Sokolow-Lyon voltage (mm) 17.9 (13.9–22.9) 18.9 (14.3–22.5) 0.763
Cornell product (mm · ms) 1093 (783–1513) 1036 (807–1409) 0.627
minSTmV5V6 (μV) 2.2 ± 39 11.6 ± 35 0.234
PTFV1 (μVms) 2856 ± 3539 3546 ± 3438 0.178
LV hypertrophy by SL voltage 7 (2) 0 (0) 0.403
LV hypertrophy by Cornell voltage 7 (2) 2 (5) 0.159
GLS, global longitudinal strain; LA, left atrium; LV, left ventricle; PTFV1, P-wave terminal force measured at lead V1.
Continuous variable as mean ± SD or median (interquartile range). Categorical variable as n (%).
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